CR11415A - Acido 4-(4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il)benzoico 465 - Google Patents

Acido 4-(4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il)benzoico 465

Info

Publication number
CR11415A
CR11415A CR11415A CR11415A CR11415A CR 11415 A CR11415 A CR 11415A CR 11415 A CR11415 A CR 11415A CR 11415 A CR11415 A CR 11415A CR 11415 A CR11415 A CR 11415A
Authority
CR
Costa Rica
Prior art keywords
tert
butilpirazol
adamantilcarbamoil
benzoico
acid
Prior art date
Application number
CR11415A
Other languages
English (en)
Inventor
Martin Packer
James Stewart Scott
Andrew Stocker
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11415A publication Critical patent/CR11415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El Ócido 4-(4-(2-adamantilcarbamoil)-5-tert-butilpirazol-l-il)benzoico y sales farmaceuticamente aceptables de este y una fora cristalina particular del agente.
CR11415A 2007-11-06 2010-05-06 Acido 4-(4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il)benzoico 465 CR11415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98573507P 2007-11-06 2007-11-06
PK10808 2008-02-04

Publications (1)

Publication Number Publication Date
CR11415A true CR11415A (es) 2010-08-27

Family

ID=42759138

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11415A CR11415A (es) 2007-11-06 2010-05-06 Acido 4-(4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il)benzoico 465

Country Status (17)

Country Link
US (1) US20110060022A1 (es)
EP (1) EP2217232A1 (es)
JP (1) JP2011502978A (es)
KR (1) KR20100095439A (es)
CN (1) CN101909621A (es)
AU (1) AU2008326226B2 (es)
BR (1) BRPI0819177A2 (es)
CA (1) CA2703781A1 (es)
CO (1) CO6270318A2 (es)
CR (1) CR11415A (es)
DO (1) DOP2010000135A (es)
EA (1) EA201000701A1 (es)
EC (1) ECSP10010159A (es)
IL (1) IL205455A0 (es)
MX (1) MX2010005048A (es)
WO (1) WO2009060232A1 (es)
ZA (1) ZA201003031B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316087B2 (en) 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
WO2009098501A1 (en) * 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
CN102066335A (zh) * 2008-04-22 2011-05-18 阿斯利康(瑞典)有限公司 取代的嘧啶-5-甲酰胺281

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528395A (ja) 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
DE602004027171D1 (de) * 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2006132436A1 (ja) * 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物

Also Published As

Publication number Publication date
BRPI0819177A2 (pt) 2015-05-05
DOP2010000135A (es) 2010-06-30
CA2703781A1 (en) 2009-05-14
JP2011502978A (ja) 2011-01-27
KR20100095439A (ko) 2010-08-30
IL205455A0 (en) 2010-12-30
EA201000701A1 (ru) 2010-12-30
AU2008326226B2 (en) 2011-10-20
AU2008326226A1 (en) 2009-05-14
MX2010005048A (es) 2010-07-28
CO6270318A2 (es) 2011-04-20
ECSP10010159A (es) 2010-06-29
ZA201003031B (en) 2011-10-26
CN101909621A (zh) 2010-12-08
US20110060022A1 (en) 2011-03-10
EP2217232A1 (en) 2010-08-18
WO2009060232A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
CR11415A (es) Acido 4-(4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il)benzoico 465
UY28493A1 (es) Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento.
ATE519764T1 (de) Spiroindolinon-derivate
RS54457B1 (en) CRYSTAL (R) - (E) -2- (4- (2- (5- (1- (3,5-Dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl) -1H- PIRAZOL-1-IL) ETHANOL AND ITS USE AS FGFR INHIBITOR
IL237820A (en) Using a History of 4- (1-Carboxy-Ethylcarbamoyl) -4- (5- [2,1] Ditheolan-3-Il-Pentanoylamino) - Butyric Acid for Drug Preparation
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
DK2235017T3 (da) Spiroindolinonderivater som anticancermidler
CR20110219A (es) Ácidos naftilacéticos
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
ECSP11010825A (es) Dabigatrán para la cateterización cardiaca intervencionista percutanea.
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
UY32299A (es) Composiciones farmacéuticas líquidas
AR063027A1 (es) Derivados de sulfonamida
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CL2010000281A1 (es) Formulacion oral en forma de tableta de 9-[(2,2-dimetil-propilamino)-metil]-minociclina; metodo de preparacion; formulacion inyectable del mismo; utiles en el tratamiento de una infeccion.
RS52381B (en) 2-METHYL-1- (PHENYLSULPHONYL) -4- (PIPERAZIN-1-IL) -1H-BENZIMIDAZOLE KAO 5-HYDROXYTRIPAMINE-6 LIGAND
NO20092134L (no) Kombinasjonsprodukt for bruk i behandling av inflammatoriske lidelser
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
ES2530436T3 (es) Combinación

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)